{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:53:40Z","timestamp":1792011220879,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T00:00:00Z","timestamp":1486512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.urolonc.2017.01.025","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T21:48:12Z","timestamp":1489873692000},"page":"183-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy"],"prefix":"10.1016","volume":"35","author":[{"given":"E. David","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew V.","family":"Schally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehonathan H.","family":"Pinthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman L.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc G.","family":"Rick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc B.","family":"Garnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Dahdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.R.","family":"Beveridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.01.025_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0024-3205(90)90296-4","article-title":"De novo biosynthesis of FSH like peptide by the human prostate","volume":"47","author":"Hurkadli","year":"1990","journal-title":"Life Sci"},{"key":"10.1016\/j.urolonc.2017.01.025_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/bjc.1990.42","article-title":"Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates","volume":"61","author":"Hurkadli","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ar.1092270308","article-title":"Immunocytochemical localization of follicle stimulating hormone in normal human stomach","volume":"227","author":"Mandrekar","year":"1990","journal-title":"Anat Rec"},{"key":"10.1016\/j.urolonc.2017.01.025_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pros.2990180402","article-title":"Prostate\u2014an extrapituitary source of follicle-stimulating hormone (FSH): occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents","volume":"18","author":"Garde","year":"1991","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2017.01.025_bib5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(01)61831-7","article-title":"Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)","volume":"161","author":"Ben-Josef","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib6","first-page":"45","article-title":"The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy","volume":"28","author":"Heracek","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.urolonc.2017.01.025_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12954\/PI.13019","article-title":"Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer","volume":"1","author":"Ide","year":"2013","journal-title":"Prostate Int"},{"key":"10.1016\/j.urolonc.2017.01.025_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5489\/cuaj.2545","article-title":"Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer","volume":"9","author":"Hoare","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2017.01.025_bib9","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","article-title":"Expression of follicle-stimulating hormone receptor in tumor blood vessels","volume":"363","author":"Radu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.01.025_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1471-2407-13-246","article-title":"Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases","volume":"13","author":"Siraj","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib11","first-page":"5","article-title":"The role of the FSH system in the development and progression of prostate cancer","volume":"10","author":"Crawford","year":"2014","journal-title":"Am J Hematol Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3892\/or.2013.2278","article-title":"Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1alpha signaling in human epithelial ovarian cancer","volume":"29","author":"Zhang","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.urolonc.2017.01.025_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2008.02.044","article-title":"Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy","volume":"266","author":"Ushio-Fukai","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2017.01.025_bib14","doi-asserted-by":"crossref","first-page":"418340","DOI":"10.1155\/2013\/418340","article-title":"The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton","volume":"2013","author":"Roberts","year":"2013","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib15","first-page":"305","article-title":"Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia","volume":"29","author":"Soulitzis","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.urology.2006.03.010","article-title":"Role of vascular endothelial growth factor in prostate cancer","volume":"68","author":"Delongchamps","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.01.025_bib17","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/ERC-15-0123","article-title":"Regulation of vascular endothelial growth factor in prostate cancer","volume":"22","author":"de Brot","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0960-0760(97)00189-1","article-title":"Effects of LHRH-analogues on mitogenic signal transduction in cancer cells","volume":"65","author":"Emons","year":"1998","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.urolonc.2012.03.005","article-title":"The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies","volume":"31","author":"Gartrell","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jcp.22491","article-title":"Potential role of follicle-stimulating hormone (FSH) and transforming growth factor (TGFbeta1) in the regulation of ovarian angiogenesis","volume":"226","author":"Kuo","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/cr.2008.70","article-title":"Activation of the PI3K\/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma","volume":"18","author":"Huang","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.urolonc.2017.01.025_bib22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/en.2008-0850","volume":"150","author":"Alam","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.urolonc.2017.01.025_bib23","first-page":"1213","article-title":"Tumor-derived vascular endothelial growth factor (VEGF)\u2014a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway","volume":"39","author":"Liu","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib24","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2017.01.025_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib26","first-page":"288","article-title":"Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)","volume":"76","author":"Goldray","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2017.01.025_bib27","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2017.01.025_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fendo.2013.00097","article-title":"Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health","volume":"4","author":"Choi","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.urolonc.2017.01.025_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/acel.12331","article-title":"FSH regulates fat accumulation and redistribution in aging through the Ga\/Ca(2+)\/CREB pathway","volume":"14","author":"Liu","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.urolonc.2017.01.025_bib30","doi-asserted-by":"crossref","first-page":"R790","DOI":"10.1152\/ajpregu.00728.2009","article-title":"Follicle-stimulating hormone, interleukin-1, and bone density in adult women","volume":"298","author":"Cannon","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0196-9781(99)00130-8","article-title":"Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis","volume":"20","author":"Schally","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.urolonc.2017.01.025_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K","article-title":"Peptide analogs in the therapy of prostate cancer","volume":"45","author":"Schally","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2017.01.025_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/edrv-7-1-44","article-title":"Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective","volume":"7","author":"Karten","year":"1986","journal-title":"Endocr Rev"},{"key":"10.1016\/j.urolonc.2017.01.025_bib34","unstructured":"Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Cancer medicine, 5th ed. Edited by J.F. Holland, E.I. Frei, R.C.J. Bast et al. Hamilton, Ontario: B.C. Decker; 2000;pp.715\u201326"},{"key":"10.1016\/j.urolonc.2017.01.025_bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ncpendmet0399","article-title":"Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone","volume":"3","author":"Engel","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2017.01.025_bib36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/OTT.S32426","article-title":"An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer","volume":"6","author":"Rick","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2017.01.025_bib37","unstructured":"Schally AV, Halmos G, Rekasi Z, Arencibia JM. The actions of LH-RH agonists, antagonists, and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors. In: Infertility and reproductive medicine clinics of North America: GnRH analogs Edited by P. Devroey. Philadelphia: Saunders, vol. 12, pp. 17-44, 2001"},{"key":"10.1016\/j.urolonc.2017.01.025_bib38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1310286","article-title":"Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)","volume":"131","author":"Gonzalez-Barcena","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0090-4295(95)80018-2","article-title":"Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord","volume":"45","author":"Gonzalez-Barcena","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.01.025_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/frne.2001.0217","article-title":"Hypothalamic hormones and cancer","volume":"22","author":"Schally","year":"2001","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib41","first-page":"2538","article-title":"Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice","volume":"52","author":"Redding","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2017.01.025_bib42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/pros.2990240206","article-title":"Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer","volume":"24","author":"Gonzalez-Barcena","year":"1994","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2017.01.025_bib43","first-page":"275","article-title":"Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group","volume":"4","author":"Garnick","year":"2000","journal-title":"Mol Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1464-410X.2011.10708.x","article-title":"New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist","volume":"110","author":"Garnick","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.01.025_bib45","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.01.025_bib46","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/00005392-200204000-00021","article-title":"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer","volume":"167","author":"Trachtenberg","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib47","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2017.01.025_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2017.01.025_bib49","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2017.01.025_bib50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2015.08.027","article-title":"Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08","volume":"69","author":"Voog","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib51","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib52","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2017.01.025_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib54","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","article-title":"The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy","volume":"86","author":"Conteduca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib57","article-title":"Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?","volume":"1","author":"Zareba","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib58","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","article-title":"Lipoprotein lipase: from gene to obesity","volume":"297","author":"Wang","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2017.01.025_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","article-title":"GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model","volume":"32","author":"Hopmans","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib60","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1016\/S1569-9056(15)60551-6","article-title":"Treatment with an LHRH agonist, but not the LHRH antagonist degarelix, induces atherosclerotic plaque instability in ApoE\u2212\/\u2212 mice","volume":"14","author":"Knutsson","year":"2015","journal-title":"Eur J Urol Suppl"},{"key":"10.1016\/j.urolonc.2017.01.025_bib61","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1161\/01.CIR.99.13.1726","article-title":"Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice","volume":"99","author":"Moulton","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2017.01.025_bib62","doi-asserted-by":"crossref","first-page":"E813","DOI":"10.1210\/jc.2013-3186","article-title":"Signaling through FSH receptors on human umbilical vein endothelial cells promotes angiogenesis","volume":"99","author":"Stilley","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2017.01.025_bib63","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/01.CIR.83.5.1764","article-title":"Structure-dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques","volume":"83","author":"Lee","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2017.01.025_bib64","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(89)90953-7","article-title":"Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques","volume":"2","author":"Richardson","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.01.025_bib65","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","article-title":"Androgen deprivation therapy for prostate cancer results in significant loss of bone density","volume":"54","author":"Wei","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.01.025_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(02)02006-X","article-title":"Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer","volume":"61","author":"Smith","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.01.025_bib67","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12020-011-9541-7","article-title":"Role of serum FSH measurement on bone resorption in postmenopausal women","volume":"41","author":"Garcia-Martin","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.urolonc.2017.01.025_bib68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2265.2007.03005.x","article-title":"The relationship between gonadotrophins, gonadal hormones and bone mass in men","volume":"68","author":"Karim","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.urolonc.2017.01.025_bib69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3299","article-title":"Emerging therapeutic opportunities for skeletal restoration","volume":"10","author":"Kawai","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.urolonc.2017.01.025_bib70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","article-title":"IL-6, RANKL, TNF-alpha\/IL-1: interrelations in bone resorption pathophysiology","volume":"15","author":"Kwan Tat","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.urolonc.2017.01.025_bib71","doi-asserted-by":"crossref","first-page":"14925","DOI":"10.1073\/pnas.0606805103","article-title":"Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation","volume":"103","author":"Iqbal","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2017.01.025_bib72","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cyto.2010.11.011","article-title":"Follicle-stimulating hormone promotes RANK expression on human monocytes","volume":"53","author":"Cannon","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.urolonc.2017.01.025_bib73","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10585-014-9680-3","article-title":"Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone","volume":"31","author":"Zheng","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.urolonc.2017.01.025_bib74","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.urolonc.2015.05.030","article-title":"Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms","volume":"33","author":"Tivesten","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib75","doi-asserted-by":"crossref","first-page":"13361","DOI":"10.1073\/pnas.95.23.13361","article-title":"Bone homeostasis","volume":"95","author":"Rodan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2017.01.025_bib76","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cncr.24896","article-title":"Pathogenesis of osteoblastic bone metastases from prostate cancer","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","article-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes","volume":"68","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2017.01.025_bib78","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","article-title":"Morphometric evidence for bone resorption and replacement in prostate cancer","volume":"68","author":"Clarke","year":"1991","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib79","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.01.025_bib80","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib81","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1464-410X.2009.08981.x","article-title":"Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study","volume":"106","author":"Schroder","year":"2010","journal-title":"BJU Int"},{"issue":"Suppl. 6","key":"10.1016\/j.urolonc.2017.01.025_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1464-410X.2012.11215.x","article-title":"Androgen deprivation therapy: past, present and future","volume":"109","author":"Schroder","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.01.025_bib83","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.23658","article-title":"Cognitive effects of hormone therapy in men with prostate cancer: a review","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.01.025_bib84","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","article-title":"Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison","volume":"33","author":"Gonzalez","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib85","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2826.2000.00461.x","article-title":"An association of elevated serum gonadotropin concentrations and Alzheimer disease?","volume":"12","author":"Bowen","year":"2000","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1196\/annals.1323.014","article-title":"Effects of testosterone on cognitive and brain aging in elderly men","volume":"1055","author":"Moffat","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.urolonc.2017.01.025_bib87","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.62.2.188","article-title":"Free testosterone and risk for Alzheimer disease in older men","volume":"62","author":"Moffat","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.urolonc.2017.01.025_bib88","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0006-8993(00)03155-3","article-title":"Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism","volume":"892","author":"Ahlbom","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.urolonc.2017.01.025_bib89","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2826.2010.02044.x","article-title":"Androgens selectively protect against apoptosis in hippocampal neurones","volume":"22","author":"Nguyen","year":"2010","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib90","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neuroscience.2003.08.048","article-title":"Androgens modulate neuronal vulnerability to kainate lesion","volume":"122","author":"Ramsden","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.urolonc.2017.01.025_bib91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.yfrne.2009.04.015","article-title":"Protective actions of sex steroid hormones in Alzheimer\u2019s disease","volume":"30","author":"Pike","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib92","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1471-4159.2005.03318.x","article-title":"Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection","volume":"94","author":"Nguyen","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.urolonc.2017.01.025_bib93","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/j.1471-4159.2008.05341.x","article-title":"Androgens regulate neprilysin expression: role in reducing beta-amyloid levels","volume":"105","author":"Yao","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.urolonc.2017.01.025_bib94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0304-3940(03)00898-X","article-title":"Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form","volume":"350","author":"Kanemitsu","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.urolonc.2017.01.025_bib95","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1523\/JNEUROSCI.1180-10.2010","article-title":"Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment","volume":"30","author":"McAllister","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.urolonc.2017.01.025_bib96","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.exger.2004.06.019","article-title":"Low free testosterone is an independent risk factor for Alzheimer\u2019s disease","volume":"39","author":"Hogervorst","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.urolonc.2017.01.025_bib97","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0025-6196(11)62109-5","article-title":"Elevated gonadotropin levels in patients with Alzheimer disease","volume":"76","author":"Short","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.urolonc.2017.01.025_bib98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.regpep.2009.08.005","article-title":"Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats","volume":"159","author":"Telegdy","year":"2010","journal-title":"Regul Pept"},{"key":"10.1016\/j.urolonc.2017.01.025_bib99","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.npep.2009.03.001","article-title":"Effects of the LHRH antagonist Cetrorelix on the brain function in mice","volume":"43","author":"Telegdy","year":"2009","journal-title":"Neuropeptides"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917300613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917300613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:10:09Z","timestamp":1761041409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917300613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1078143917300613"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.01.025","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}